HALO vs OMCL: fair value comparison
Halozyme Therapeutics, Inc. and Omnicell, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, HALO currently sits closer to the top of our ranking by discount to fair value. HALO carries the stronger quality grade.
| HALO | OMCL | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $121.84 | $35.39 |
| 12-month range | $61.63–$121.84 | $29.57–$51.39 |
| Rank by discount to fair value | #32 of 108 Healthcare | #36 of 108 Healthcare |
| Quality grade | A | B |
| Leverage | High | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: HALO fair value analysis · OMCL fair value analysis